Literature DB >> 9419197

Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL.

A Lafeuillade1, L Chollet, G Hittinger, N Profizi, O Costes, C Poggi.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) RNA was measured in lymph node (LN) mononuclear cells of 50 patients with sustained plasma RNA of <200 copies/mL with therapy. Six patients had received a combination of three reverse transcriptase inhibitors (RTIs) since primary infection, 11 received this same combination during chronic disease, 21 received a combination of two RTIs plus a protease inhibitor (PI), and 12 received three RTIs plus a PI. The mean overall duration of therapy was 8.9 +/- 0.5 months (range, 5-24), with no significant difference between groups. LN HIV-1 RNA levels varied from undetectable to 1.7 million copies/10(6) cells according to cases. The mean LN HIV-1 RNA level was 2.99 +/- 0.42 log10 copies/10(6) cells in the 17 patients receiving three RTIs compared with 1.93 +/- 0.25 log10 copies/10(6) cells in the 33 patients receiving a PI (t test, P = .02). These data demonstrate that highly active antiretroviral regimens have unequivalent effects on LNs and invite redefinition of suboptimal therapy at this level.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9419197     DOI: 10.1086/517362

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Evolution of broadly cross-reactive HIV-1-neutralizing activity: therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations.

Authors:  Carolina B Ferreira; Alberto Merino-Mansilla; Anuska Llano; Ignacio Pérez; Isabel Crespo; Laia Llinas; Felipe Garcia; Jose M Gatell; Eloisa Yuste; Victor Sanchez-Merino
Journal:  J Virol       Date:  2013-09-04       Impact factor: 5.103

2.  Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates.

Authors:  Jennifer P Freeling; Josefin Koehn; Cuiling Shu; Jianguo Sun; Rodney J Y Ho
Journal:  AIDS Res Hum Retroviruses       Date:  2015-01       Impact factor: 2.205

3.  Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: effects on virologic, immunologic, and toxicity parameters.

Authors:  M Dybul; T W Chun; C Yoder; B Hidalgo; M Belson; K Hertogs; B Larder; R L Dewar; C H Fox; C W Hallahan; J S Justement; S A Migueles; J A Metcalf; R T Davey; M Daucher; P Pandya; M Baseler; D J Ward; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

4.  Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion.

Authors:  Olivier Bourry; Abdelkrim Mannioui; Pierre Sellier; Camille Roucairol; Lucie Durand-Gasselin; Nathalie Dereuddre-Bosquet; Henri Benech; Pierre Roques; Roger Le Grand
Journal:  Retrovirology       Date:  2010-09-26       Impact factor: 4.602

Review 5.  Perspectives on Human Immunodeficiency Virus (HIV) Cure: HIV Persistence in Tissue.

Authors:  Eli A Boritz; Daniel C Douek
Journal:  J Infect Dis       Date:  2017-03-15       Impact factor: 5.226

Review 6.  Nanodrug formulations to enhance HIV drug exposure in lymphoid tissues and cells: clinical significance and potential impact on treatment and eradication of HIV/AIDS.

Authors:  Jingwei Shao; John C Kraft; Bowen Li; Jesse Yu; Jennifer Freeling; Josefin Koehn; Rodney Jy Ho
Journal:  Nanomedicine (Lond)       Date:  2016-02-19       Impact factor: 5.307

7.  Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy.

Authors:  R G Amado; B D Jamieson; R Cortado; S W Cole; J A Zack
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients.

Authors:  Caroline Solas; Alain Lafeuillade; Philippe Halfon; Stéphane Chadapaud; Gilles Hittinger; Bruno Lacarelle
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

9.  Switch from enfuvirtide to raltegravir in virologically suppressed HIV-1 infected patients: effects on level of residual viremia and quality of life.

Authors:  Philip M Grant; Sarah Palmer; Eran Bendavid; Annie Talbot; Debbie C Slamowitz; Pat Cain; Stacy S Kobayashi; Maya Balamane; Andrew R Zolopa
Journal:  J Clin Virol       Date:  2009-10-12       Impact factor: 3.168

10.  Long-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and blood.

Authors:  Jennifer P Freeling; Josefin Koehn; Cuiling Shu; Jianguo Sun; Rodney J Y Ho
Journal:  AIDS       Date:  2014-11-13       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.